Results for isgyvenimo translation from Lithuanian to English

isgyvenimo tikimyb
2 months 2-6 months 6 months

metastazin liga bendrojo isgyvenimo
metastatic population

mediana bendrojo isgyvenimo vidurkis
(months) (months) (months) overall population 6.4 6.0 0.41

0, 66, 0, 98) , p = 0, 029 isgyvenimo tikimyb
0.66, 0.98) , p = 0.029 survival probability

pbaigtis bendrojo isgyvenimo(mn.) (mn.)
ci of

vidutin isgyvenimo trukm buvo 384 ir 373 dienos.
median survival was 384 and 373 days.

isgyvenimo atzvilgiu vorikonazolas buvo zymiai efektyvesnis nei amfotericinas b.
the survival for voriconazole was significantly greater than that for amphotericin b.

bendro isgyvenimo rizikos santykis buvo 0, 96 (95% pi:
the hazard ratio for overall survival was 0.96 (95% ci:

kaplan-meier bendrojo isgyvenimo kreivs (kg populiacija)
1 2.11 4.6figure 1kaplan-meier curves for overall survival (itt population)

pagrindinis veiksmingumo rodiklis buvo pacient isgyvenimo trukm po pirmosios operacijos.
the main measure of effectiveness was how long the patients survived after the first operation.

buvo vertinamas ketinimo gydytis populiacijos isgyvenimas pagal tolesnio stebjimo dl isgyvenimo duomenis.
survival was evaluated in the intent-to-treat population based on follow-up survival data.

1 paveikslas.kaplan-meier bendrojo isgyvenimo kreivs (kg populiacija)
25 h r (9 5% c. i.) = 1.5 9 (1.3 3 ­ 1.9 1) lo g -ra n k p -va lu e .0 0 0 126% rt+tm z10% r t o n ly1 2.11 4.6figure 1kaplan-meier curves for overall survival (itt population)

xeloda turinciu rezimu gydyt pacient bendro isgyvenimo laiko mediana buvo 703 dienos (95% pi:
median overall survival time was 703 days (95% ci:

vidutin isgyvenimo trukm buvo 442 dienos (xeloda + docetakselis) ir 352 dienos (gydyta vien docetakseliu) .
median survival was 442 days (xeloda + docetaxel) vs.352 days (docetaxel alone) .

-vyrams.epoetinu beta gydyt pacient isgyvenimas be regioninio ligos progresavimo buvo
locoregional progression-free survival was significantly shorter in patients receiving epoetin beta.